API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

Other Certificates

0

Other Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

1

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

BioCurity Pharmaceuticals

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Expanding Patent Portfolio Successes for Supportive Cancer Drugs Designed to Prevent Radia...

Details:

Expansion of Intellectual Property portfolio for its supportive care drugs under development generated cerium oxide nanoparticle technology an IV formulation for protection of normal internal tissue from radiation damage, topical formulation for protection of cancer patient.

Lead Product(s): Cerium Oxide

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2022

ASK
US

Upload
your Marketing & Sales content

BioCurity Pharmaceuticals

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Announces Presentation at ACRO Summit 2022 on Sensitizing Head and Neck Cancer to Radiatio...

Details:

BioCurity’s cerium oxide nanoparticles possess fast catalase activity in a normal tissue’s neutral pH environment and reduces radiation-induced hydrogen peroxide to molecular oxygen, thereby preventing radiation damage of normal tissue.

Lead Product(s): Cerium Oxide,Tolfenamic Acid

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2022

ASK
US

Upload
your Marketing & Sales content

BioCurity Pharmaceuticals

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

BioCurity Pharma Gets Issuance of European Patent for Reduction of Side Effects Caused by Radiation Therapy Combined with Chemotherapy

Details:

This European patent covers the use of cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for lung and pancreatic cancer patients receiving a combination of therapeutically effective doses of radiation therapy and chemotherapy.

Lead Product(s): Cerium Oxide,Radiation therapy,Chemotherapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 02, 2020

ASK
US

Upload
your Marketing & Sales content